Anileridine: Difference between revisions
Matt Pijoan (talk | contribs) m Protected "Anileridine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name = | | Verifiedfields = changed | ||
| verifiedrevid = 457130773 | |||
| IUPAC_name = Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate | |||
| image = Anileridine.png | | image = Anileridine.png | ||
| width = 150px | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|monograph|buprenorphine-hydrochloride}} | |||
| pregnancy_category = | |||
| legal_AU = S8 | |||
| legal_CA = Rx-only | |||
| legal_US = Schedule II | |||
| legal_status = | |||
| routes_of_administration = Tablets, injection | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| protein_bound = > 95% | |||
| metabolism = [[Liver|Hepatic]] | |||
| elimination_half-life = | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 144-14-9 | | CAS_number = 144-14-9 | ||
| ATC_prefix = N01 | | ATC_prefix = N01 | ||
| ATC_suffix = AH05 | | ATC_suffix = AH05 | ||
| ATC_supplemental = | | ATC_supplemental = | ||
| PubChem = 8944 | | PubChem = 8944 | ||
| DrugBank = | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| C = 22 | H = 28 | N = 2 | O = 2 | | DrugBank = DB00913 | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 8600 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 71Q1A3O279 | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D02941 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 61203 | |||
| ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| ChEMBL = 1201347 | |||
<!--Chemical data--> | |||
| C=22 | H=28 | N=2 | O=2 | |||
| molecular_weight = 352.47 g/mol | | molecular_weight = 352.47 g/mol | ||
| smiles = O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3 | |||
| InChI = 1/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 | |||
| InChIKey = LKYQLAWMNBFNJT-UHFFFAOYAF | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = LKYQLAWMNBFNJT-UHFFFAOYSA-N | |||
| melting_point = 83 | | melting_point = 83 | ||
}} | }} | ||
'''Anileridine''' (trade name '''Leritine''') is a synthetic [[ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Anileridine''' (trade name: '''Leritine''') is a synthetic [[analgesic]] drug and is a member of the [[piperidine]] class of analgesic agents developed by Merck & Co. in the 1950s.<ref>{{US Patent|2897204}}</ref> It differs from [[pethidine]] (meperidine) in that the ''N''-methyl group of meperidine is replaced by an ''N''-aminophenethyl group, which increases its analgesic activity. | |||
Anileridine is no longer manufactured in the US or Canada.<ref>{{Cite web |last= |first= |title=Discontinued Prescription Drug Products |publisher=Canadian Pharmacists' Association |date= |url=http://www.pharmacists.ca/content/hcp/tools/drugnews/discontinued.htm |accessdate=28 July 2008}}</ref> | |||
==Administration== | ==Administration== | ||
As [[ | As [[Tablet (pharmacy)|tablets]] or [[Injection (medicine)|injection]].<ref>{{Cite web |last= |first= |title=Pharmaceutical Information - LERITINE |publisher=RxMed |date= |url=http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20%28General%20Monographs-%20L%29/LERITINE.html |accessdate=16 June 2010 }}</ref> | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours. It is mostly metabolized by the [[liver]]. | Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.<ref>{{Cite web |last= |first= |title=Anileridine Consumer Information |publisher=MedicineNet |date= |url=http://www.medicinenet.com/anileridine-oral_tablet/article.htm |accessdate=28 July 2008}}</ref> It is mostly metabolized by the [[liver]]. | ||
==References== | |||
{{Reflist|2}} | |||
{{Analgesics}} | {{Analgesics}} | ||
{{General anesthetics}} | {{General anesthetics}} | ||
{{Opioidergics}} | |||
[[Category:Piperidines]] | |||
[[Category:Synthetic opioids]] | |||
[[Category: | [[Category:General anesthetics]] | ||
[[Category:Anilines]] | |||
[[Category:Ethyl esters]] | |||
[[Category:Mu-opioid agonists]] | |||
[[Category:Analgesics]] | |||
Revision as of 18:44, 8 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
Routes of administration | Tablets, injection |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | > 95% |
Metabolism | Hepatic |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C22H28N2O2 |
Molar mass | 352.47 g/mol |
3D model (JSmol) | |
Melting point | 83 °C (181.4 °F) |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Anileridine |
Articles |
---|
Most recent articles on Anileridine Most cited articles on Anileridine |
Media |
Powerpoint slides on Anileridine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Anileridine at Clinical Trials.gov Clinical Trials on Anileridine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Anileridine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Anileridine Discussion groups on Anileridine Patient Handouts on Anileridine Directions to Hospitals Treating Anileridine Risk calculators and risk factors for Anileridine
|
Healthcare Provider Resources |
Causes & Risk Factors for Anileridine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s.[1] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada.[2]
Administration
Pharmacokinetics
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[4] It is mostly metabolized by the liver.
References
- ↑ Template:US Patent
- ↑ "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Retrieved 28 July 2008.
- ↑ "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
- ↑ "Anileridine Consumer Information". MedicineNet. Retrieved 28 July 2008.
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to verified fields
- Piperidines
- Synthetic opioids
- General anesthetics
- Anilines
- Ethyl esters
- Mu-opioid agonists
- Analgesics